Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of electrochemotherapy alone or combined with aldesleukin or lansoprazole in metastatic melanoma
2012-002059-40Phase 2Terminated
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2012
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lansoprazole, bleomycin and aldesleukin in melanoma and cutaneous melanoma (CM) (3 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Systemic antitumor immune response. Started Sep 2012; status: terminated.
02
Drugs
lansoprazolebleomycinaldesleukin
03
Conditions
melanomacutaneous melanoma (CM)
Beyond the preview
Go deeper on 2012-002059-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002059-40.